ArticleFrontiers in pharmacology2026
Compound phellodendron decoction promotes post-fistulotomy wound healing by downregulating neutrophil extracellular traps formation: evidence from a randomized trial and mechanistic studies.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Persistent inflammation and dysregulated neutrophil extracellular traps (NETs) are key factors impairing postoperative wound healing. While the traditional formula Compound Phellodendron Decoction (CPD) is clinically effective in sitz-bath therapy, its mechanism of action, particularly concerning the novel therapeutic target NETosis, remains unknown. We hypothesized that CPD accelerates healing by downregulating NET formation. Methods: In a randomized, double-blind, placebo-controlled trial, 60 patients post-anal fistulotomy received daily topical ultrasonically nebulized CPD (n = 30) or placebo (n = 30). Primary endpoints were healing time and scores for edema, pain, and exudation on days 3 and 7. Secondary outcomes included inflammatory cytokine levels, hydroxyproline, angiogenesis, and direct histological and ultrastructural assessment of NETs in granulation tissue. To dissect the underlying mechanism, we investigated the effect of CPD on NETosis in primary human neutrophils, measuring NET formation, reactive oxygen species (ROS) generation, and expression of key mediators (CitH3, PAD4). Results: CPD significantly shortened wound healing time (40.23 ± 9.61 vs. 45.84 ± 13.29 days, P < 0.001) and improved clinical scores. It modulated inflammation by elevating IL-2 and IL-10 while reducing IL-6, IL-22, and TNF-α. Critically, immunofluorescence and transmission electron microscopy revealed a substantial reduction in NETosis in CPD-treated tissues, accompanied by enhanced angiogenesis. Conclusion: CPD facilitates wound healing through a dual mechanism involving systemic immunomodulation and attenuation of NETosis by the ROS/PAD4 axis in neutrophils. Our study identifies CPD as a promising NETosis-targeted therapeutic agent for chronic wound management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.